Acute Liver Failure Clinical Trial
— MARS in HHOfficial title:
Molecular Adsorbent Recirculating System (MARS®) for the Treatment of Patients With Hypoxic Hepatitis - a Prospective Randomized Controlled Clinical Study
Hypoxic hepatitis (HH) is reported to be the most frequent cause of elevated aminotransferase levels in hospital. Up to 10 % of critically ill patients develop HH during the course of their intensive care unit (ICU) stay. Occurrence of HH is a life threatening event and ICU-mortality is reported to be up to 60%. Early therapeutic intervention is of central prognostic importance in patients with HH to improve the hemodynamic impairment as early as possible, to reduce hyperammonemia and hepatic encephalopathy, to avoid progression of organ failure and to improve outcome. Studies reported that Molecular Adsorbent Recirculating System (MARS®) therapy improved the hemodynamic situation in patients with acute and acute on chronic liver failure. The study hypothesis is that MARS® therapy in critically ill patients with severe HH improves hepatic hemodynamics and function and consecutively the course of the disease. 40 patients with suffering of severe HH with aminotransferase levels > 40 times the upper limit of normal of more than 12 hours will be randomized 1:1 to MARS® therapy (n=20) or conventional therapy (n=20). 4 MARS®-sessions will be performed on three consecutive days, each for at least 12 hours. Treatment will be continued under special circumstances. The maximum duration of the treatment phase is 7 days. The primary endpoint is the difference of the indocyanine plasma disappearance rate at day 7. The expected duration of the study is 2 years.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | |
Est. primary completion date | June 2017 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - presence of severe hypoxic hepatitis with aminotransferase levels > 40 times the upper limit of normal - duration of hypoxic hepatitis more than 12 hours - age >/= 18 years Exclusion Criteria: - age < 18 years - pregnancy - DNR - order - liver cirrhosis - Cardiopulmonary resuscitation with unknown neurological outcome and/or hypoxic brain damage - Expected survival of less than 24 hours |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Austria | Medical University Vienna, Dpt. of Internal Medicine 3, Div. of Gastroenterology and Hepatology | Vienna | |
Germany | University Medical Center Hamburg-Eppendorf | Hamburg |
Lead Sponsor | Collaborator |
---|---|
Medical University of Vienna |
Austria, Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | difference of the indocyanine plasma disappearance rate (ICG-PDR) | The primary endpoint will be the difference of the indocyanine plasma disappearance rate (ICG-PDR) at day 7. Only in case of major differences in baseline values of ICG-PDR we will use the change from baseline to day 7 of ICG-PDR (delta ICG-PDR) as outcome. Assuming normal distribution of ICG-PDR, we will formally test the null-hypothesis of no difference between intervention group and control using an independent sample t-test. The assumption of a normal distribution will be founded on visually inspecting a histogram and using the Shapiro Wilks test for normal distribution. If the assumption of normality does not hold data will be compared using the Mann-Whitney U-test. A p-level of < 0.05 will be considered statistically significant. Furthermore a linear random coefficient model will be used to incorporate daily measurements of ICG-PDR during the course of the study in terms of a repeated measures design. | Days 1-7 | No |
Secondary | duration of vasopressor support | 1-28 | No | |
Secondary | ICU - length of stay | 1-28 | No | |
Secondary | hospital - length of stay | 1-90 | No | |
Secondary | 7-day mortality | 7 days | No | |
Secondary | 28 day mortality | 28 days | No | |
Secondary | number of organ failure on day 7 | 7 days | No | |
Secondary | number of organ failure on day 28 | 28 days | No | |
Secondary | markers of liver function | especially occurrence of jaundice (defined as total bilirubin levels > 3 mg/dL) will be documented | 1-28 | No |
Secondary | number of vasopressor free days | 28 days | No | |
Secondary | systemic hemodynamics | systemic blood pressure, heart rate, cardiac index, central venous oxygen saturation, systemic vascular resistance index, global enddiastolic volume index, stroke volume variation, extravascular lung water index, pulse pressure variation, intrathoracic blood volume index, cardiac function index, central venous pressure | 7 days | No |
Secondary | number of complications of HH | following complications will be encountered: cholestasis, secondary sclerosing cholangitis, hepatic encephalopathy grade 3 & 4, hypoglycemia, intraabdominal hypertension, new onset of infections, renal failure, hepatopulmonary syndrome | 1-28 | Yes |
Secondary | biomarkers | blood samples will be collected the assess markers of inflammation, markers of endothelial function, markers of cardiac function, markers of cholestasis, markers of liver cell necrosis etc | 0-28 | No |
Secondary | duration of mechanical ventilation | 1-28 | No | |
Secondary | necessity of renal replacement therapy | 1-28 | No | |
Secondary | duration of renal replacement therapy | 1-28 | No | |
Secondary | 90 days mortality | 90 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05491135 -
Hepatocyte Microbeads for Acute Liver Failure
|
Phase 1/Phase 2 | |
Terminated |
NCT01937130 -
Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF
|
Phase 2 | |
Withdrawn |
NCT05940610 -
The Safety and Efficacy of MSC-EVs in Acute/Acute-on-Chronic Liver Failure
|
Phase 1/Phase 2 | |
Terminated |
NCT01875874 -
Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF)
|
Phase 2 | |
Not yet recruiting |
NCT01435421 -
Breath Test for Patients With Acute Liver Disease for Early Detection of the Need for Transplant or Recovery
|
N/A | |
Completed |
NCT00245310 -
Indocyangreen Elimination in Cirrhosis and Acute Liver Failure
|
N/A | |
Withdrawn |
NCT03629015 -
Safety Study of Stemchymal® in Acute Liver Failure
|
Phase 1 | |
Recruiting |
NCT04621812 -
Role of Fecal Microbiota in Predicting Graft Rejection and Sepsis Among Recipients of Living Donor Liver Transplant in First Year.
|
||
Active, not recruiting |
NCT02833064 -
Biomarkers in Liver Failure
|
||
Not yet recruiting |
NCT06285253 -
miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial
|
Phase 1 | |
Recruiting |
NCT03882346 -
Study to Evaluate Safety and Efficacy of LifeLiver in Acute or Acute-on-Chronic Liver Failure Patients
|
Phase 2 | |
Recruiting |
NCT05689645 -
F573 for Injection for the Treatment of Liver Injury/Failure
|
Phase 2 | |
Not yet recruiting |
NCT05772585 -
Characterization of Metabolomic Fingerprints in Patients With Acute Liver Failure and Acute-on-chronic Liver Failure With Hepatic Encephalopathy
|
||
Completed |
NCT00655304 -
The Effect of Prometheus (R) Liver Support Dialysis on Cerebral Metabolism in Acute Liver Failure
|
N/A | |
Completed |
NCT00059267 -
Prevention of Recurrent Hepatitis B After Liver Transplantation
|
N/A | |
Active, not recruiting |
NCT05413083 -
Evaluation of Cardiac Function in Acutely Decompensated Cirrhosis
|
||
Recruiting |
NCT05146336 -
CytOSorb TreatMent Of Critically Ill PatientS Registry
|
||
Withdrawn |
NCT04089969 -
Cardiac Risk Assessment Using Standard of Care Versus CTA and Heart Flow FFRct
|
N/A | |
Completed |
NCT02460510 -
Role of Hypertonic Saline Versus Mannitol in the Management of Raised Intracranial Pressure in Patients With ALF
|
N/A | |
Completed |
NCT01872767 -
Spectrum, Profile and Outcome of Infections in Patients With Cirrhosis and/ or Acute on Chronic Liver Failure
|
N/A |